Trans-gingival or Subcrestal Short Implants Posterior Maxilla Bone Changes (NCT05975138) | Clinical Trial Compass
CompletedNot Applicable
Trans-gingival or Subcrestal Short Implants Posterior Maxilla Bone Changes
Italy22 participantsStarted 2021-06-15
Plain-language summary
two groups of inserted implants: trans-gingival and under-bone level; difference in the marginal bone loss at six months from placement between the two groups of implant positioned in the posterior atrophic maxilla
Who can participate
Age range18 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\) indications for an implant-prosthetic rehabilitation of a single edentulism in the upper posterior arch, on the basis of an accurate diagnosis and treatment planning;
* 2\) the bone crest must be healed (at least six months after tooth loss);
* 3\) residual bone crest width ≥6 mm;
* 4\) presence of an available bone height between 4.5 and 8.5 mm on the floor of the maxillary sinus in the area of the planned implant insertion;
* 5\) patient age \>18 years;
* 6\) the patient must not wear any type of removable prosthesis on the treated area;
* 7\) the patient must be able to follow the study protocol;
* 8\) written informed consent
Exclusion Criteria:
* 1\) acute myocardial infarction in the last 2 months;
* 2\) uncontrolled bleeding disorders;
* 3\) uncontrolled diabetes (HBA1c \> 7.5);
* 4\) head/neck radiotherapy in the last 24 months;
* 5\) immunocompromised patients, HIV positive or undergoing chemotherapy in the last 5 years;
* 6\) current or past treatment with intravenous bisphosphonates;
* 7\) psychological or psychiatric problems;
* 8\) alcohol or drug abuse;
* 9\) The local exclusion criterion is the presence of uncontrolled periodontal disease